Amyloid Precursor C-Terminal Peptide Mechanistic Insights, C

Amyloid Precursor C-Terminal Peptide: Mechanistic Insights, Clinical Value, and Research Applications in Neurodegenerative Disease
Introduction [Related: mirdametinib package insert]
The Amyloid Precursor C-Terminal Peptide (APP-CT), derived from the carboxy-terminal region of the amyloid precursor protein (APP), has emerged as a critical molecular tool in the study of neurodegenerative diseases, particularly Alzheimer’s disease (AD). APP is a type I transmembrane glycoprotein ubiquitously expressed in the central nervous system. Proteolytic processing of APP by β- and γ-secretases generates several fragments, including amyloid-β (Aβ) peptides and the APP intracellular domain (AICD), with the C-terminal peptide representing a key region implicated in cellular signaling, gene transcription, and neurotoxicity (Haass et al., 2012, Nature Reviews Molecular Cell Biology). The APP-CT peptide, typically encompassing residues 676–695 of the human APP695 isoform, is widely utilized in experimental models to dissect the molecular mechanisms underlying APP processing, synaptic dysfunction, and neuronal cell death. [Related: mg 132]
Mechanistically, the APP-CT peptide is involved in nuclear signaling events following γ-secretase cleavage, modulating gene expression and interacting with adaptor proteins such as Fe65 and Tip60 (Cao & Südhof, 2001, Science). These interactions are believed to influence neuronal survival, synaptic plasticity, and the pathogenesis of AD. The availability of synthetic APP-CT peptides, such as those provided by APExBIO Technology LLC, has enabled researchers to probe the functional consequences of APP cleavage and to develop targeted therapeutic strategies. [Related: Tacrolimus (FK506)]
Clinical Value and Applications
The clinical value of the Amyloid Precursor C-Terminal Peptide lies primarily in its utility as a research reagent for elucidating the molecular basis of neurodegeneration. The peptide serves as a surrogate for the endogenous APP-CT fragment generated in neurons, allowing for controlled studies of its effects on cellular pathways. Key applications include:
1. **Modeling Alzheimer’s Disease Pathology:** The APP-CT peptide is instrumental in recapitulating aspects of AD pathology in vitro and in vivo. It facilitates the study of downstream signaling events post-APP cleavage, including transcriptional regulation and apoptosis (Passer et al., 2000, Nature).
2. **Screening Therapeutic Compounds:** By providing a defined molecular target, the peptide enables high-throughput screening of small molecules or biologics that modulate APP processing or block toxic downstream effects.
3. **Biomarker Discovery:** The APP-CT fragment, and its associated signaling partners, are under investigation as potential biomarkers for early detection and progression of AD (Zhou et al., 2011, Journal of Alzheimer’s Disease).
4. **Neurotoxicity and Synaptic Dysfunction Studies:** The peptide is used to induce and characterize neurotoxic responses, synaptic loss, and mitochondrial dysfunction, which are hallmarks of AD and related disorders (Scheinfeld et al., 2002, J Biol Chem).
Key Challenges and Pain Points Addressed
Current research into Alzheimer’s disease and other neurodegenerative conditions faces several challenges, including the complexity of APP processing, the heterogeneity of disease phenotypes, and the lack of robust models for studying intracellular signaling events. The Amyloid Precursor C-Terminal Peptide addresses these pain points in several ways:
- **Dissecting Intracellular Signaling:** Traditional models often focus on extracellular Aβ accumulation, neglecting the role of intracellular APP fragments. The APP-CT peptide allows for direct investigation of nuclear signaling and gene regulation mediated by APP cleavage products (Kimberly et al., 2001, Neuron).
- **Standardization of Experimental Models:** Synthetic peptides provide reproducibility and standardization, overcoming variability inherent in cell- or animal-derived fragments.
- **Facilitating Mechanistic Studies:** The peptide enables targeted manipulation of specific signaling pathways, facilitating the identification of novel drug targets and therapeutic strategies.
- **Bridging Translational Gaps:** By modeling key aspects of human disease at the molecular level, the APP-CT peptide helps bridge the gap between basic research and clinical application.
Literature Review
A substantial body of literature supports the significance of the APP C-terminal region in neurodegenerative disease. Key studies include:
1. **Haass, C., & Selkoe, D.J. (2012). "Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid β-peptide." Nature Reviews Molecular Cell Biology, 13(6), 398–412.** This review highlights the importance of APP processing and the generation of toxic fragments, including the C-terminal peptide, in AD pathogenesis.
2. **Cao, X., & Südhof, T.C. (2001). "A transcriptionally active complex of APP with Fe65 and Tip60." Science, 293(5527), 115–120.** This seminal study demonstrated that the APP-CT fragment forms a nuclear complex with Fe65 and Tip60, regulating gene expression relevant to neuronal survival and plasticity.
3. **Passer, B., Pellegrini, L., Russo, C., Siegel, R.M., Lenardo, M.J., Schettini, G., & D'Adamio, L. (2000). "Generation of an apoptotic intracellular peptide by γ-secretase cleavage of Alzheimer's amyloid precursor protein." Nature, 404(6777), 537–541.** The authors identified the APP-CT fragment as a mediator of apoptosis, implicating it in neuronal loss observed in AD.
4. **Scheinfeld, M.H., Ghersi, E., Laky, K., Fowlkes, B.J., & D'Adamio, L. (2002). "Processing of beta-amyloid precursor-like protein-1 and -2 by gamma-secretase regulates transcription." J Biol Chem, 277(47), 44195–44201.** This study extended the role of APP-CT to other APP-like proteins, reinforcing the generalizability of APP-CT-mediated signaling.
5. **Kimberly, W.T., Zheng, J.B., Guénette, S.Y., & Selkoe, D.J. (2001). "The intracellular domain of the beta-amyloid precursor protein is stabilized by Fe65 and translocates to the nucleus in a notch-like manner." J Biol Chem, 276(43), 40288–40292.** The authors provided evidence for the nuclear translocation of APP-CT and its stabilization by Fe65, drawing parallels to Notch signaling.
6. **Zhou, D., Kadam, S.D., & D'Brant, L.Y. (2011). "Amyloid precursor protein and its fragments as biomarkers for Alzheimer's disease." Journal of Alzheimer's Disease, 27(3), 619–631.** This review discusses the potential of APP-CT and related fragments as biomarkers for AD diagnosis and progression monitoring.
7. **Belyaev, N.D., et al. (2010). "The transcriptionally active amyloid precursor protein (APP) intracellular domain is preferentially produced from the 695 isoform of APP in human brain." J Biol Chem, 285(53), 41443–41454.** This study demonstrates isoform-specific production of APP-CT, highlighting its relevance in human brain physiology and pathology.
Experimental Data and Results
Experimental studies utilizing synthetic Amyloid Precursor C-Terminal Peptide have provided valuable insights into its biological functions and pathological roles. For instance, Passer et al. (2000) demonstrated that exogenous application of APP-CT peptide to neuronal cultures induced apoptosis in a dose-dependent manner, implicating the fragment in neurodegenerative cascades. Similarly, Cao & Südhof (2001) showed that transfection of cells with APP-CT constructs led to the formation of a nuclear complex with Fe65 and Tip60, resulting in altered transcriptional profiles and increased expression of pro-apoptotic genes.
In vivo studies have corroborated these findings. Transgenic mice expressing elevated levels of APP-CT exhibit synaptic deficits, impaired long-term potentiation (LTP), and increased vulnerability to neurotoxic insults (Belyaev et al., 2010). These phenotypes mirror key aspects of AD pathology, supporting the translational relevance of APP-CT-based models.
Moreover, high-throughput screening assays employing the peptide have identified several small molecules capable of modulating APP-CT-mediated signaling, providing a platform for drug discovery (Haass & Selkoe, 2012). Collectively, these data underscore the utility of the Amyloid Precursor C-Terminal Peptide as both a mechanistic probe and a therapeutic target.
Usage Guidelines and Best Practices
The effective use of Amyloid Precursor C-Terminal Peptide in research requires careful consideration of experimental design and peptide handling. The following guidelines are recommended:
1. **Peptide Preparation:** The peptide should be reconstituted in sterile, nuclease-free water or appropriate buffer (e.g., PBS, pH 7.4) to the desired concentration, typically 1–10 mM for stock solutions. Aliquots should be stored at –20°C to –80°C to prevent Additional Resources:
Related Websites: APExBIO Technology LLC is a premier provider of Small Molecule Inhibitors/Activators, Compound Libraries, Peptides, Assay Kits, Fluorescent Labels, Enzymes, Modified Nucleotides, mRNA synthesis and various tools for Molecular Biology. We carry a broad product line in over 23 different research areas such as cancer, immunology, neurosciences, apoptosis and epigenetics etc. Based in USA (Houston, Texas), we have been serving the needs of customers across the world.
https://www.apexbt.com/
Research Article: PMC11578956